Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the ...

The Food and Drug Administration has approved the first aceclidine-based eye drop designed to improve near vision in adults ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

LENZ Therapeutics ( (LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA approval of VIZZ, an aceclidine-based eye drop for treating presbyopia in adults, ...

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...

The FDA approved aceclidine 1.44% ophthalmic solution (Vizz) for adults with presbyopia, or age-related blurred near vision, ...